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Background: There are some cases that show unresponsiveness to intravenous immunoglobulin (IVIG) treatment in patients with Kawasaki 
disease (KD). High incidence of coronary artery sequela is seen in unresponsive cases. There are some attempts, for example, by Kobayashi et al 
(Circulation, 2006) and by Egami et al (J Pediatr, 2006), to predict the unresponsive cases by making scoring system using clinical features and 
general laboratory data. However, there is no report based on biomarker. Pentraxin 3 (PTX3) is produced at the site of inflammation in response to 
primary inflammation stimuli. And it is used as a new biomarker for vasculitis. We explored the Capability of PTX3 as a biomarker for predicting IVIG 
unresponsiveness in KD in this study.
Methods: 56 patients with KD are enrolled. Blood samples are collected at before and 2 days after IVIG, 1, 3, 6 month later from the onset of KD. 
PTX3 values are compared with IVIG unresponsive scoring system by Kobayashi et al. (Circulation, 2006). PTX3 was measured by ELISA method.
Results: 1. Mean value of PTX3 before IVIG was 23.6 ng/ml (vs. age-matched control: 3.6 ng/ml). 2. PTX3 values in unresponsiveness cases 
(n=7) was significantly high compared to responsive cases (n=49) (55.3 vs. 18.9; p<0.01). There were two coronary artery lesion (CAL) cases in the 
unresponsive cases and PTX3 values in these cases were 63.7 and 89.3 ng/ml. 3. There is statistical positive correlation between PTX3 and score 
points by Kobayashi et al. (r=0.641, p=0.000), suggesting the reliability of PTX3 as a prediction marker for IVIG unresponsiveness in KD. 4. Sensitivity 
and specificity of PTX3 as IVIG unresponsiveness prediction were 85.7 and 95.9 % if cut-off value of PTX3 was set at 40 ng/ml. 5. PTX3 values in 
recovery phase (i.e., at 1, 3, 6 mo after onset of KD) were 7.4 (p<0.05), 4.3 (n.s.), 3.8 (n.s.) respectively (statistical difference with age-matched 
control is given in parenthesis). This suggests that by one month after onset of KD silent vasculitis will continue.
Conclusions: These data suggest that PTX3 can be a candidate biomarker for prediction of unresponsiveness and CAL formation in patients with KD.
